Jeroncelvein , a specialized pharmaceutical manufacturing company, announced on the 20th that it had officially introduced 'Selbain Injection', a specialized pain and inflammation treatment drug, as a presenter at the Spring Academic Conference of the Korean Neurosurgical Association.
About 600 people attended the '2025 Korean Neurosurgical Society Spring Academic Conference' held by the Korean Neurosurgical Society at the Gwanggaeto Hall Convention Hall of Sejong University on the 16th and shared the latest knowledge.
At this academic conference, CEO Deok-gyu Kim of Geroncellbein explained the following topics: ▲PDRN mechanism ▲application areas by product ▲medical treatment areas ▲Geroncellbein’s patented technology under the topic, “Is PDRN a panacea?”
Prism Technology (Prism-T), a patented technology of GeronCellbein, is a method of manufacturing nucleic acid fragments of uniform size using GeronCellbein's own unique technology. It produces products with small and uniform molecules of a certain size, and has excellent absorption and absorption capacity in the body with a molecular weight that is up to 5 times smaller than existing PDRN.
Kim Deok-gyu, CEO of Geronselvein, said, “We expect it to be widely used in various clinical settings as well as for pain and spinal diseases in neurosurgery,” and “It will become an important treatment option that meets the needs of patients based on excellent quality and safety.”
He added, “Starting with the general direction presented at this spring conference of the Korean Neurosurgical Society, we plan to actively carry out activities so that ‘Selbainju’ can lead the market.”
- See more related articles
You must be logged in to post a comment.